Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jul 24, 2024; 15(7): 945-952
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.945
Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report
Gui-Qin Peng, Hai-Chi Song, Wan-Yi Chen
Gui-Qin Peng, Hai-Chi Song, Wan-Yi Chen, Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China
Co-first authors: Gui-Qin Peng and Hai-Chi Song.
Author contributions: Peng GQ and Song HC contributed equally to manuscript writing and editing, and data collection; Chen WY contributed to conceptualization and supervision. All authors read and approved the final manuscript. Peng GQ and Song HC contributed equally to this work as co-first authors.
Supported by Wu Jieping Medical Foundation, No. 320.6750.2022-20-25; and Chongqing Health Commission, No. [2020]68.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wan-Yi Chen, MSc, Associate Chief Pharmacist, Department of Pharmacy, Chongqing University Cancer Hospital, No. 181 Hanyu Road, Shapingba District, Chongqing 400030, China. wanyichen_cquch@163.com
Received: March 11, 2024
Revised: May 21, 2024
Accepted: June 5, 2024
Published online: July 24, 2024
Processing time: 126 Days and 21.7 Hours
Core Tip

Core Tip: Over the past two decades, molecular targeted therapies have improved clinical outcomes significantly for non-small cell lung cancer (NSCLC) patients with either epidermal growth factor receptor (EGFR) mutation or c-ros oncogene 1 (ROS1) fusion. Nevertheless, EGFR/ROS1 co-mutation is a rare event in NSCLC, and the standard treatment for such cases is still equivocal. We report an EGFR/ROS1 co-mutation in an NSCLC patient who remained clinically stable after 53 months of treatment with crizotinib. This is the longest progression-free survival reported in the literature. This case suggested that crizotinib may be a potential choice for NSCLC patients with such EGFR/ROS1 co-mutations.